Blau Farmacêutica (BLAU3) Q4 2025 earnings summary

Executive summary

• Achieved record organic investments, focusing on biosimilars and monoclonal antibodies, with significant progress in R&D and capacity expansion projects.

• Divested from Prothya, strengthening the balance sheet, supporting a net cash position, and sharpening focus on core hospital business.

• Net revenue declined 3% year-over-year to BRL 1.7 billion, but gross profit rose 4% due to cost reductions and improved mix.

• Net income surged 39% to BRL 297 million, driven by operational resilience, divestment gains, and FX effects.

• Record shareholder remuneration, including stock bonuses and dividends, reached BRL 582 million in total, with BRL 182 million in cash payouts.

Financial highlights

• Revenue for 2025 was BRL 1.7 billion, a 3% decrease year-over-year due to bid delays and product mix shifts.

• Gross margin improved by 260 bps to 40.1%, and EBITDA margin reached 24.9% (recurring 22.8%).

• Net income reached BRL 297 million, a 39% increase year-over-year.

• Launches contributed 7.5% of revenue, up 18% year-over-year.

• Free cash flow to equity was BRL 166 million, down 14% year-over-year due to higher investments.

Outlook and guidance

• Expecting accelerated launches and resumed revenue growth in 2026 as Anvisa reduces analysis queue and new production lines come online.

• Won federal bids for Epoetin alfa and other products at better prices and volumes, supporting 2026 results.

• Margin improvement anticipated from cost dilution, automation, and higher-value product mix.

• International expansion and partnerships, especially in monoclonal antibodies, are key growth drivers.

• Focus on biosimilars and monoclonal antibodies as key growth drivers, leveraging upcoming patent expirations.